Evaluation of a cardiac prevention and rehabilitation programme for all patients at first presentation with coronary artery disease

European Journal of Cardiovascular Prevention & Rehabilitation

Volumn 9, Issue 6, 2002, Pages 355-359

  Fox, Kevin F ^a   Wood, David A ^a   Wright, Melissa ^a   Bond, Sharon ^b   Nuttall, Michaela ^b   Arora, Barbara ^b   Dawson, Ellen ^b   Devane, Patricia ^b   Sutcliffe, Steven J ^a   Brown, Ken ^b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b Bromley Hospitals NHS Trust   (United Kingdom)

Author keywords

coronary artery disease; prevention; rehabilitation

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL;

ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; EUROPE; EVALUATION; FOLLOW UP; GENERAL PRACTITIONER; HEALTH CARE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; ORGANIZATION; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; SCREENING; SMOKING; UNITED KINGDOM;

ANTILIPEMIC AGENTS; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; GREAT BRITAIN; HUMANS; HYPERLIPIDEMIAS; OUTCOME ASSESSMENT (HEALTH CARE); PLATELET AGGREGATION INHIBITORS; PROGRAM EVALUATION; SMOKING CESSATION;

EID: 0036932046     PISSN: 17418267     EISSN: 17418275     Source Type: Journal    
DOI: 10.1177/174182670200900609     Document Type: Article

References (8)

1. The National Service Framework for CoronaryHeart Disease. HMSO 2000.
2. Fox KF, Nuttall M, Wood DA, Wright M, Arora B, Dawson E, et al A cardiac prevention and rehabilitation programme for allpatients at first presentation with coronary artery disease in thepopulation. Heart 2001; 85: 533–538.
3. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drugtherapies in coronary patients from fifteen countries. Principal resultsfrom EUROASPIRE II. Eur Heart J 2001; 22: 554–572.
4. Sutcliffe SJ, Fox KF, Wood DA. How to set up and run a Rapid Access Chest PainClinic. Br J Cardiol 2000; 7: 692–702.
5. Sutcliffe SJ, Sutcliffe AK, Wood DA. The clinical incidence of fatal and non-fatal coronary heartdisease in the population. Heart 1999; 81(Suppl1):28.
6. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al The effect of Pravastatin on coronary events after myocardialinfarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009.
7. McAlistair FA, Lawson FME, Teo KK, Armstrong PW. Randomised trials of secondary prevention programmes in coronaryheart disease: A systematic review. BMJ 2001; 323: 957–962.
8. British Cardiac Society, BritishHyperlipidaemia Association, British Hypertension Society, British DiabeticAssociation. Joint British recommendations onprevention of coronary heart disease in clinical practice:Summary. BMJ 2000; 320: 705–708.